Patents Assigned to Merck
  • Glucose-responsive insulin conjugates
    Patent number: 9889205
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo
  • Surface anchored light chain bait antibody display system
    Patent number: 9890378
    Abstract: The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. Embodiments of the invention provide a system in which a bait complexed with a monovalent antibody fragment can be captured prior to secretion in a host cell by virtue of surface displaying an antibody light chain and utilizing the covalent interaction of this light chain with the heavy chain of an antibody molecule that is co-expressed in the same host. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of using the system for identifying antibodies that bind specifically to an antigen of interest.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: February 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hussam Hisham Shaheen, Dongxing Zha
  • Materials for organic electroluminescence devices
    Patent number: 9893292
    Abstract: The present invention relates to novel materials which can be used in organic electronic devices, in particular electroluminescent devices, and are certain derivatives of fused aromatic systems.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: February 13, 2018
    Assignee: Merck Patent GmbH
    Inventors: Holger Heil, Arne Buesing, Philipp Stoessel, Horst Vestweber
  • Heterocyclic compounds
    Patent number: 9893299
    Abstract: The invention concerns heterocyclic compounds and electronic devices, in particular organic electroluminescent devices, containing these compounds.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: February 13, 2018
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Nils Koenen
  • FGF-18 compound dosing regimen
    Patent number: 9889179
    Abstract: The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administrations every 3 weeks, 4 weeks or 5 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-adminsitration of an anti-inflammatory drug.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 13, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring
  • Materials for electronic devices
    Patent number: 9893297
    Abstract: The present invention relates to compounds of the formula (I), to the use of compounds of the formula (I) in electronic devices and electronic devices comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: February 13, 2018
    Assignee: Merck Patent GmbH
    Inventors: Irina Martynova, Adam W. Franz, Christof Pflumm, Amir Hossain Parham, Arne Buesing, Rémi Manouk Anémian, Anja Gerhard
  • Pigments
    Patent number: 9890287
    Abstract: The present invention relates to pigments based on bismuth compounds and to the use thereof, preferably as laser-absorbent additive, and to a process for the preparation thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 13, 2018
    Assignee: Merck Patent GmbH
    Inventors: Helge Bettina Kniess, Franciscus Gerardus Henricus Van Duijnhoven, Franciscus Wilhelmus Maria Gelissen
  • Process for making substituted quinazoline compounds
    Patent number: 9890128
    Abstract: The present invention is directed to a process for making Substituted Quinazoline Compounds of formula (I): which are useful for the treatment and prophylaxis of HCMV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: February 13, 2018
    Assignees: MERCK SHARP & DOHME CORP., AICURIS ANTI-INFECTIVE CURES GMBH
    Inventors: Michael Luzung, Guy Humphrey, Bangping Xiang, Kevin M. Belyk, Stephen Mark Dalby, Wilfried Schwab, Burkhard Klenke, Tom Moody, Gareth Brown
  • AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST
    Publication number: 20180037554
    Abstract: The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.
    Type: Application
    Filed: February 1, 2016
    Publication date: February 8, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Rongze Kuang, Yeon-Hee Lim, Michael Man-Chu Lo, Pauline C. Ting, Purakkattle Biju, Manuel de Lera Ruiz, Sylvia J. Degrado, Alexander L. Tung, Timothy J. Henderson, Liwu Hong, Jae-Hun Kim, Dong Won-Shik Kim, Joe Lee, Jie Wu, Heping Wu, Yushi Xiao, Tao Yu, Gang Zhou, Xiaohong Zhu, Kevin D. McCormick, Jayaram R. Tagat, Dong Xiao, Tanweer Khan, Jianhua Cao, Michael Berlin, Yonglian Zhang
  • PIPERIDINE DERIVATIVES AND LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20180037820
    Abstract: Disclosed are compounds of the formula I, liquid-crystalline media comprising the compounds of formula I, and the use of these liquid-crystalline media in liquid-crystal displays.
    Type: Application
    Filed: August 4, 2017
    Publication date: February 8, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Achim GOETZ, Rocco FORTTE, Martin Engel, Sabrina MAAG, Thorsten KODEK
  • ERK inhibitors
    Patent number: 9884048
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: February 6, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Phieng Siliphaivanh, Joey Methot, Kathryn Ann Lipford, Danielle Molinari, David L. Sloman, David Witter, Hua Zhou, Christopher Boyce, Xianhai Huang, Jongwon Lim, David Guerin, Ganesh Babu Karunakaran, Raman Kumar Bakshi, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu
  • Acylguanidines for treating osteoarthritis
    Patent number: 9884814
    Abstract: The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: February 6, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Christos Tsaklakidis, Markus Klein, Paul Czodrowski
  • Glucose-responsive insulin conjugates
    Patent number: 9884125
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: February 6, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Christopher R. Moyes
  • RORgammaT inhibitors
    Patent number: 9884043
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: February 6, 2018
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • Disulfide masked prodrug compositions and methods
    Patent number: 9884886
    Abstract: The present invention relates to disulfide masked prodrug compounds of formula I, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione: W—P(V)LG??(Formula I), wherein P(V)LG is a pentavalent phosphorus leaving group; and W is: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics. Once administered, the prodrug is metabolized in vivo into an active metabolite in a process termed bioactivation.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: February 6, 2018
    Assignee: Merck Sharp & Dohme
    Inventor: Gabor Butora
  • SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20180028509
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 1, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, Yonglian Zhang, Sherman Tim Waddell, Andrew Stamford, John S. Wai, Paul J. Coleman, John M. Sanders, Ronald Ferguson, Thomas H. Graham, Hong Li
  • ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
    Publication number: 20180030007
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Application
    Filed: October 9, 2017
    Publication date: February 1, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell
  • Factor IXa Inhibitors
    Publication number: 20180030036
    Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
    Type: Application
    Filed: December 7, 2015
    Publication date: February 1, 2018
    Applicants: MERCK SHARP & DOHME CORP., MOCHIDA PHARMACEUTICAL CO., LTD
    Inventors: Ting Zhang, Yi-Heng Chen, Liangqin Guo, Alan Hruza, Tianying Jian, Bing Li, Dongfang Meng, Dann L. Parker, Edward C. Sherer, Harold B. Wood, Isao Sakurada
  • Use of cyclohexanol derivatives as antimicrobial active compounds
    Patent number: RE46698
    Abstract: The present invention relates to the use of at least one cyclohexanol derivative of the formula (I) and/or (II) as antimicrobial active compound or as anti-acne, antidandruff, antiperspirant or deodorant active compound, to preparations comprising these compounds, and to specific cyclohexanol derivatives and to a process for the preparation thereof.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: February 6, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Thomas Rudolph, Tatjana Best
  • Medical injector pen
    Patent number: D810283
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Angela M. Amend Kwasnik, Benjamin R. Bartfield, Peter Basile, Jeffrey C. Givand, Philip G. Green, Sharad Gupta, Christin L. O'Neill, Steven Carl Persak, Robert Stianchi, Ari Tao Adler, Florian Altmann, Thomas Junk, Florian Kössler, Martin Meier, Scott R. Mackie, Pernilla Danielsson